文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

瑞德西韦5天或10天疗程治疗重症Covid-19患者

Remdesivir for 5 or 10 Days in Patients with Severe Covid-19.
PubMed 文献 · N Engl J Med · 2020-05-27
一句话结论在不需要机械通气的重症Covid-19患者中,5天与10天瑞德西韦疗程在改善临床状态方面无显著差异,但无安慰剂对照,获益幅度无法确定。

该随机、开放标签、3期试验纳入397例住院确诊SARS-CoV-2感染、呼吸环境空气时氧饱和度≤94%且有肺炎影像学证据的患者,1:1随机接受静脉瑞德西韦5天(200例)或10天(197例),首日200 mg,后续每日100 mg。主要终点为第14天7分序贯量表临床状态。第14天临床改善≥2分者5天组64%、10天组54%;校正基线临床状态后,10天组第14天临床状态分布与5天组相似(P=0.14)。最常见不良事件为恶心(9%)、呼吸衰竭恶化(8%)、丙氨酸氨基转移酶升高(7%)和便秘(7%)。

要点

  • 纳入标准:住院确诊SARS-CoV-2感染、呼吸环境空气时氧饱和度≤94%、有肺炎影像学证据。
  • 随机接受静脉瑞德西韦5天(200例)或10天(197例),首日200 mg,后续每日100 mg一次。
  • 第14天临床改善≥2分:5天组64% vs 10天组54%;校正基线后两组第14天临床状态分布相似(P=0.14)。
  • 最常见不良事件:恶心9%、呼吸衰竭恶化8%、丙氨酸氨基转移酶升高7%、便秘7%。
  • 结论:不需要机械通气的重症Covid-19患者中,5天与10天疗程无显著差异;无安慰剂对照,获益幅度无法确定。

适用人群与场景

  • 住院确诊SARS-CoV-2感染、呼吸环境空气时氧饱和度≤94%、有肺炎影像学证据的患者。
  • 不需要机械通气的重症Covid-19患者。

处置流程与药物剂量

  • 静脉瑞德西韦:第1天200 mg,后续每日100 mg一次;5天组疗程5天,10天组疗程10天。

研究设计与关键结果

  • 随机、开放标签、3期试验,397例患者随机并开始治疗(5天组200例,10天组197例)。
  • 治疗中位时长:5天组5天(四分位距5至5),10天组9天(四分位距5至10)。
  • 基线时10天组临床状态显著差于5天组(P=0.02)。
  • 第14天序贯量表临床改善≥2分:5天组64% vs 10天组54%;校正基线临床状态后,10天组第14天临床状态分布与5天组相似(P=0.14)。
  • 最常见不良事件:恶心9%、呼吸衰竭恶化8%、丙氨酸氨基转移酶升高7%、便秘7%。

证据类型、等级与局限

  • 证据类型:随机、开放标签、3期试验。
  • 无安慰剂对照,获益幅度无法确定。

对床旁实践的改变

  • 在不需要机械通气的重症Covid-19患者中,该试验未显示5天与10天瑞德西韦疗程有显著差异。
  • 作者指出,因无安慰剂对照,获益幅度无法确定。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Remdesivir is an RNA polymerase inhibitor with potent antiviral activity in vitro and efficacy in animal models of coronavirus disease 2019 (Covid-19).

METHODS: We conducted a randomized, open-label, phase 3 trial involving hospitalized patients with confirmed SARS-CoV-2 infection, oxygen saturation of 94% or less while they were breathing ambient air, and radiologic evidence of pneumonia. Patients were randomly assigned in a 1:1 ratio to receive intravenous remdesivir for either 5 days or 10 days. All patients received 200 mg of remdesivir on day 1 and 100 mg once daily on subsequent days. The primary end point was clinical status on day 14, assessed on a 7-point ordinal scale.

RESULTS: In total, 397 patients underwent randomization and began treatment (200 patients for 5 days and 197 for 10 days). The median duration of treatment was 5 days (interquartile range, 5 to 5) in the 5-day group and 9 days (interquartile range, 5 to 10) in the 10-day group. At baseline, patients randomly assigned to the 10-day group had significantly worse clinical status than those assigned to the 5-day group (P = 0.02). By day 14, a clinical improvement of 2 points or more on the ordinal scale occurred in 64% of patients in the 5-day group and in 54% in the 10-day group. After adjustment for baseline clinical status, patients in the 10-day group had a distribution in clinical status at day 14 that was similar to that among patients in the 5-day group (P = 0.14). The most common adverse events were nausea (9% of patients), worsening respiratory failure (8%), elevated alanine aminotransferase level (7%), and constipation (7%).

CONCLUSIONS: In patients with severe Covid-19 not requiring mechanical ventilation, our trial did not show a significant difference between a 5-day course and a 10-day course of remdesivir. With no placebo control, however, the magnitude of benefit cannot be determined. (Funded by Gilead Sciences; GS-US-540-5773 ClinicalTrials.gov number, NCT04292899.).

来源:N Engl J Med,查看原文。版权归原作者所有。

参考来源

  1. Goldman JD, Lye DCB, Hui DS, et al. Remdesivir for 5 or 10 Days in Patients with Severe Covid-19. N Engl J Med. 2020. PMID: 32459919. doi:10.1056/NEJMoa2015301

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。